Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Myeloid 1Head & Neck 1Gastrointestinal 1CNS 1

Conditions

Pancreatic Neoplasms 685Cholangiocarcinoma 113Biliary Tract Neoplasms 95Neoplasms 69Neoplasm Metastasis 66Gallbladder Neoplasms 61Colorectal Neoplasms 49Bile Duct Neoplasms 40Carcinoma, Non-Small-Cell Lung 37Adenocarcinoma 28Carcinoma, Hepatocellular 26Stomach Neoplasms 22Liver Neoplasms 21Colonic Neoplasms 21Ovarian Neoplasms 20Lung Neoplasms 19Breast Neoplasms 18Rectal Neoplasms 15Carcinoma, Pancreatic Ductal 15Pancreatic Adenocarcinoma 13Esophageal Neoplasms 13Sarcoma 12Carcinoma 11Small Cell Lung Carcinoma 10Urinary Bladder Neoplasms 9Gastrointestinal Neoplasms 9Advanced Pancreatic Cancer 9Triple Negative Breast Neoplasms 8Squamous Cell Carcinoma of Head and Neck 8Recurrence 8

Interventions

Panitumumab 1PLX8394 1IFL protocol 1Gemcitabine 1Cetuximab 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Histiocytosis × Gemcitabine × Gastrointestinal × Clear all
NCT05786924 2026-04-21

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Servier

Phase 1/2 Recruiting
554 enrolled
CNSGastrointestinalHead & NeckMyeloidThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Histiocytosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡